On the other hand, poor demand in underdeveloped countries restrains the growth to some extent. However, several growth opportunities in emerging markets have proven to be beneficial for the market growth.
Increase in prevalence of various cancer types, rise in demand for cost-efficient biosimilar monoclonal antibodies, and upsurge in likelihood of epidemic or pandemic outbreaks drive the growth of the global Monoclonal Antibodies Market. On the other hand, poor demand in underdeveloped countries restrains the growth to some extent. However, several growth opportunities in emerging markets have proven to be beneficial for the market growth.
The global monoclonal antibodies market was estimated at $146.64 billion in 2020 and is expected to hit $390.58 billion by 2030, registering a CAGR of 10.2% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and wavering market trends.
Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/12154
COVID-19 scenario-
- Rise in necessity for treatments available on a global scale has encouraged rapid development of a large number of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralizing monoclonal antibodies (mAbs).
- Thus, COVID-19 infection uplifted growth and opportunities for the key players of the monoclonal antibodies market.
The global monoclonal antibodies market is analyzed across source, indication, end user, and region. Based on source, the human segment accounted for more than two-fifths of the total market revenue in 2020, and is expected to dominate by the end of 2030. The same segment would also cite the fastest CAGR of 11.0% from 2021 to 2030.
Based on indication, the cancer segment contributed to nearly three-fifths of the total market share in 2020, and is projected to rule the roost by 2030. The same segment would also showcase the fastest CAGR of 10.7% throughout the forecast period.
Based on region, North America held the major share in 2020, garnering more than two-fifths of the global market. The market across Asia-Pacific, on the other hand, would cite the fastest CAGR of 11.7% during the forecast period. Other regions profiled in the report include LAMEA and Europe.
The key market players analyzed in the global monoclonal antibodies market report include Abbott Laboratories, AstraZeneca plc., Amgen Inc., Eli Lilly, GlaxoSmithKline Plc., Bayer AG, Johnson & Johnson, Pfizer, Merck & Co. Inc., and Novartis. These market players have incorporated several strategies including partnership, expansion, collaboration, joint ventures, and others to brace their stand in the industry.
“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”
Trending Reports [2021-2028]:
Cell Therapy Market Size Expected to Reach $48,115.40 Million by 2027
Neurology Devices Market Size Expected to Reach $17,410 Million by 2026
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975